Marker Therapeutics Inc (MRKR)

[TomP1]

Reason why the phase 2 trial was expanded from 80 to 120 patients:


"... patients in the second remission were seen as the next target for a creative approach. Patients in the first remission were not yet seen as available for a novel technology. And this was still considered to be a novel technology. Given that we’ve got a lot of experience now with the TNBC subpopulation, we have an opportunity to go into this healthier population in first remission. And so we’ve essentially flipped into a space that both has no other medications available during that first remission and can benefit from having a larger population that has a healthier substrate.

So we expect great things actually from that study. And the PIs, we talked a lot with the PIs in making this change and they are very excited about the opportunities that sort of presented themselves with this."